🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What a fantastic dinner with my favourite collegues Alessandro Di Federico Filippo Gallina from Italy and Molly Li from @CHUK at #ELCC2025 Paris: connecting 🫁 researchers from all over the world

Pleased to share our editorial on uncommon EGFR mutations in JTO & JTO CRR written with my good friend Molly Li, accompanying the neat article by the one and only Alfredo Addeo MD. So much more to uncover about EGFRm NSCLC 🤓 link is free till 27 May: ddei5-0-ctp.trendmicro.com/wis/clicktime/…

🔥 Nature Medicine 🆙 ✅Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations 🎯ORR of 34% (95%CI, 23–47) and mPFS of 9.3 mo (95%CI, 7.6–11.4) in　EGFRm NSCLC 👥 Dr. Shen Zhao ✅NCT04152499, NCT05631262 OncoAlert nature.com/articles/s4159…

🎖️I am humbly honored to have been nominated ✅ IASLC 2025 Board of Directors Election 🎯2025 Undesignated Seat #2 🗣️Vision for🌏Global🌎Education🌍 🗳️I would truly appreciate your valuable support iaslc.org/2025-undesigna…

Full support to Alex A. Adjei for President-Elect in 2025 IASLC Board of Directors Election! I have worked with him for 10+ years, inspired by his strong leadership, vision, advocacy, and dedication to patient care, research and publication, and mentoring the next generations.

Very happy to share that I have been nominated for IASLC board of directors! Contributing to fostering, mentoring and teaching the new generation of colleagues combined with moving the field of thoracic oncology forward is my passion. Please vote lnkd.in/e3B24W8r

My thanks to my fellow #coinvestigators for giving me opportunity to present our data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at AACR #AACR25. The strong & rapid #targetengagement confers superior #efficacy c.f. 1st generation G12Ci. ✔️ORR 30%; DCR

A prelude to our #NPC #Nasopharyngealcarcinoma #NPC Edu Session with Profs Brigette Ma CUHK Medicine and Anna Spreafico #ASCO25 Can’t wait to meet everyone in a month! ascopubs.org/doi/pdfdirect/…

Grateful for the opportunity to write this editorial in JTO & JTO CRR with Dr Cathleen Park accompanying the NEOS trial on peri-op osimertinib jto.org/article/S1556-…. Very timely before NeoADAURA is presented at #ASCO2025! Practice-changing or not? The chapter unfolds… 📖

Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in NEJM Presentation today by 1@only Charlie Rudin #ASCO25

EORTC Lung Group present at ASCO 2025! Excellent oral abstract discussions of Chair Jordi Remon and Secretary Lizza Hendriks EORTC

Happy to bump in to friends at ASCO Molly Li

#ASCO25 most enjoyable one so far! Delighted to present our research, plan collabs and most importantly celebrate milestones with friends. Discussing data with people real-time in the congress beats listening online any day. Now time to combat jet lag 😵‍💫

Stoked to share my third editorial in JTO & JTO CRR this year! Dr Bironzo and I discuss SKIPPirr, which demonstrates significant reduction of Amivantamab-related IRR with oral dexamethasone prophylaxis. Definitely practice-changing, link is free till 26 Jul ddei5-0-ctp.trendmicro.com/wis/clicktime/…

Thank you Hidehito HORINOUCHI for giving his inspiring lecture on IIT research in the CTONG-Young (Chinese Thoracic Oncology Research Group Young) conference! A lot to learn from how JCOG runs trials! #LCSM #CTONG #JCOG

Welcome to #hongkong 🇭🇰 Christian Rolfo! A pleasure being able to host International Society of Liquid Biopsy annual meeting in my home city. Thanks to colleagues at HKU Medicine for organising this #HKIOF25 meeting. #LCSM #precisionmedicine CUHK Medicine APODDC Asia Pacific Coalition against Lung Cancer

📢 #Happy to share w/ #LCSM community! After 3+ years of work, we are pleased to share our #cost_effectiveness modelling for #lungcancer 🫁 #screening 🏥📸 in both #high-risk populations determined by both #smoking & #non-smoking risk factors e.g. family history for an entire

Excellent study, looks like OncotypeDx in lung cancer